Rigel Pharmaceuticals Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Rigel Pharmaceuticals's estimated annual revenue is currently $46.8M per year.
- Rigel Pharmaceuticals received $71.8M in venture funding in April 2018.
- Rigel Pharmaceuticals's estimated revenue per employee is $155,000
- Rigel Pharmaceuticals has 302 Employees.
- Rigel Pharmaceuticals grew their employee count by 4% last year.
- Rigel Pharmaceuticals currently has 4 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
What Is Rigel Pharmaceuticals?
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
Rigel Pharmaceuticals News
Each buying and selling session display one-of-a-kind actions and patterns about Rigel Pharmaceuticals, Inc. RIGL), Biotechnology stock.
With the previous 100-day trading volume average of 1.32 million shares, Rigel Pharmaceuticals (RIGL) recorded a trading volume of 1.56 ...
Acadian Asset Management LLC boosted its position in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) by 548.3% in the second ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
Rigel Pharmaceuticals Funding
|2003-05-01||$46.0M||Lead Investor: MPM C||Article|
|2003-06-30||$46.0M||Common Stock||MPM Capital||Article|
|2009-09-19||$108.3M||Undisclosed||Credit Suisse Securities (USA)||Article|
|2011-05-26||$Undisclosed||Undisclosed||Jefferies & Company Inc, J P Morgan Securities LLC||Article|
|2012-10-04||$130.0M||Undisclosed||Jefferies & Company Inc, J P Morgan Securities LLC||Article|
|2017-10-05||$69.7M||Undisclosed||BMO Capital Markets Corp||Article|
Rigel Pharmaceuticals Executive Hires
|2002-10-31||Susan Scher||VP Strategic Relations||Article|
|2003-10-08||Robin Cooper||SVP Pharmaceutical Sciences||Article|
|2006-06-07||Ryan D. Maynard||VP Finance/CFO||Article|
|2008-02-27||Daniel B. Magilavy||VP Clinical Research||Article|
|2016-03-09||Anne-Marie Duliege||chief medical officer||Article|
|2016-09-16||Eldon C. Mayer||EVP/Chief commercial officer||Article|
|2016-10-10||Esteban Masuda||SVP Research||Article|
|2017-12-18||Nelson Cabatuan||interim principal accounting officer||Article|
Rigel Pharmaceuticals Staff Cuts
|Date||Number of Employees||Location||Reference|
|2009-02-04||20 % of Staff||Article|